Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Rimegepant, Rimegepant (PF-07899801)
Rimegepant/BHV3000 · 1 trial · 1 indication
Pain freedom will be assessed in adolescent population (≥ 12 to \< 18 years of age) on a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe).
| Arm | Type | Description |
|---|---|---|
| BHV3000 (active drug) | ACTIVE_COMPARATOR | BHV3000 (rimegepant) 75 mg or 50 mg ODT |
| Placebo | PLACEBO_COMPARATOR | Matching 75 mg or 50 mg ODT placebo |
| Name | Type | Description |
|---|---|---|
| Rimegepant/BHV3000 | DRUG | BHV3000 (rimegepant) 75 mg or 50 mg ODT |
| Matching placebo | DRUG | Matching 75 mg or 50 mg ODT placebo |
Inclusion Criteria: 1. History of migraine (with or without aura) for \> 6 months before Screening according to the IHS Classification ICHD-319 specifications for pediatric migraine. History may be verified using both medical records and recall by the participant and/or participant's parent(s)/lega...
Rimegepant is an investigational small molecule being developed for migraine, including acute treatment of migraine, preventive treatment of migraine, and migraine with or without aura. It is also being studied for pediatric migraine and for intermittent prevention of menstrual migraine. Rimegepant is in Phase 3 clinical development.
Rimegepant is a small molecule that targets the calcitonin gene-related peptide (CGRP) receptor, which plays a role in migraine pathophysiology. By blocking this receptor, rimegepant is designed to treat and prevent migraine attacks. It is being studied for acute and preventive treatment of migraine.
Rimegepant is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting Phase 3 clinical trials of rimegepant for migraine indications, including pediatric migraine and menstrual migraine prevention.
Rimegepant is in Phase 3 clinical development. It is not FDA approved and remains investigational. Pfizer is conducting multiple Phase 3 trials, including studies in pediatric subjects for acute migraine treatment, adolescents with frequent migraine, and women for intermittent prevention of menstrual migraine.
Rimegepant is being studied in several Phase 3 trials, including NCT04743141 for acute migraine treatment in pediatric subjects, NCT06616194 for adolescents with frequent migraine, and NCT06641466 for intermittent prevention of menstrual migraine. A Phase 2 trial, NCT03732638, evaluated rimegepant for migraine prevention in adults.
Yes, Rimegepant is also known as PF-07899801 and BHV3000. These alternative names refer to the same investigational drug being developed by Pfizer for migraine treatment and prevention. Rimegepant is currently in Phase 3 clinical trials for multiple migraine indications.